Levels of phospho-SYK, -GAB1 (a reported downstream effector of SYK), -PKACα, and -TBK1 were all found enhanced in anti-IgM–stimulated CLL cells from ibrutinib-treated patients. Here, TBK1 is linked to B-cell chronic lymphocytic leukemia.